EPA Proposes Rollback of Ethylene Oxide Sterilization Emissions Limits
The U.S. Environmental Protection Agency has proposed weakening restrictions on emissions of ethylene oxide (EtO) from commercial sterilization facilities that sterilize medical devices.
EtO plays a critical role in healthcare manufacturing. The gas is used to sterilize approximately half of all medical devices in the United States (about 20 billion devices annually) including catheters, stents, surgical kits, pacemakers, and ventilators. Manufacturers rely on EtO because it can sterilize delicate plastics and complex device assemblies that cannot tolerate heat, radiation, or moisture.
However, EtO is also a known human carcinogen. Long-term exposure has been linked to leukemia, lymphoma, breast cancer, and neurological damage. Millions of Americans live near sterilization facilities that emit small quantities of the gas, raising environmental justice concerns.
The Biden administration issued stricter rules in 2024 that were expected to reduce EtO emissions by roughly 90 percent through tighter limits and continuous emissions monitoring. The current EPA proposal would loosen those requirements, including removing round-the-clock monitoring mandates. The agency argues the earlier rules could have forced sterilization plants to close, potentially disrupting the supply of sterile medical devices.
Industry groups, including AdvaMed, support the proposed rollback, citing the need to maintain reliable sterilization capacity for the healthcare system. Environmental organizations, meanwhile, argue that existing pollution-control technologies can reduce emissions without shutting down facilities and warn that relaxing standards could increase cancer risks for nearby communities.
The EPA estimates the proposed rule could save sterilization companies about $43 million annually in compliance costs. The proposal will undergo a 45-day public comment period before the agency finalizes the rule, likely within the next year.
Our Take
The EPA’s proposal highlights the ongoing public health paradox surrounding ethylene oxide. The gas is essential for sterilizing many modern medical devices, yet long-term exposure poses documented cancer risks.
For the medical device industry, the issue underscores a deeper structural problem: the healthcare system remains heavily dependent on a single sterilization technology while alternatives such as radiation, vaporized hydrogen peroxide, and nitrogen dioxide sterilization are being explored. And many devices cannot yet transition without redesign and extensive validation.
Regardless of how the regulatory debate unfolds, the long-term trend is clear. Manufacturers and sterilization providers will continue to face pressure to reduce EtO emissions, diversify sterilization technologies, and strengthen supply-chain resilience.
The real challenge for regulators and industry alike will be balancing environmental protection, community health, and uninterrupted access to sterile medical devices.
FDA Warns Wild Arabic Herbs Over Product Cancer Claims
FDA Warns Wild Arabic Herbs Over Cancer Claims for Herbal Product FDA issued a warning letter to Wild Arabic Herbs after reviewing the company’s website and determining that its “Edral-17t” product was marketed as an unapproved new drug. FDA cited claims that the...
FDA Warns Amazon for Unapproved Drugs Sold On Its Website
FDA Issues Warning Letter to Amazon for Unapproved Drug Products FDA issued a warning letter to Amazon.com, Inc. after purchasing and reviewing products sold through Amazon’s website and fulfilled through Amazon’s logistics network. The products identified were...
FDA Warns Leading Edge Health Over Unapproved New Drugs
FDA Warning Letter Targets Erectin Stimulating Gel and VigRX Delay Wipes FDA issued a warning letter to Leading Edge Health Inc. after reviewing the company’s website and determining that two sexual health products were being marketed as unapproved new drugs. The...
FDA Targets Online Marketing of Unapproved Drugs
FDA Issues 14 Warning Letters Targeting Online Unapproved Drug Sales The U.S. Food and Drug Administration (FDA) has issued a coordinated series of warning letters targeting companies marketing unapproved drug products online, signaling an intensified enforcement...
FDA Approves First Treatment to Reduce Risk of Acute Pancreatitis
FDA Approves First Treatment Proven to Reduce Acute Pancreatitis Risk in Severe HypertriglyceridemiaAn important example of the distinction between surrogate endpoints and clinical outcomes in drug development The U.S. Food and Drug Administration (FDA) has approved...
One Contaminated Alcohol Pad, Multiple Recalls
A Lesson in Medical Device Supply Chain Quality At first glance, Cardinal Health's recent recall of Webcol™ Alcohol Prep Pads appears straightforward. A commonly used healthcare product was found to be contaminated with Paenibacillus phoenicis, creating a potential...